From https://adisinsight.springer.com/drugs/800028651

Originator PolyMedix
Developer Innovation Pharmaceuticals
Class Amides; Anti-infectives; Anti-inflammatories; Anti-acnes; Anti-bacterials; Antivirals; Foot disorder therapies; Guanidines; Peptidomimetics; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules
Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors; Virus internalization inhibitors
Orphan Drug Status No
New Molecular Entity Yes
Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
Phase II COVID 2019 infections; Skin and soft tissue infections; Stomatitis; Ulcerative proctitis
Phase 1 Inflammatory bowel diseases
Preclinical Acne; Alphavirus infections; Atopic dermatitis; Bunya virus infections; Coronavirus infections; Ebola virus infections; Hidradenitis suppurativa; Marburg virus disease; Nipah virus infections; West Nile virus infections; Zika virus infection
No development reported Diabetic foot ulcer; Otitis; Wounds
Discontinued Intestinal infections; Ophthalmic infections; Ulcerative colitis
Most Recent Events
25 Oct 2021Preclinical trials in Ebola virus infections in USA (unspecified route)
25 Oct 2021Preclinical trials in Marburg virus disease in USA (unspecified route)
25 Oct 2021Preclinical trials in Nipah virus infections in USA (unspecified route)

GLTA Longs only